

2017 年度

学会発表(国内学会)

2017.07 第 14 回日本臨床腫瘍学会

1. Development of new agents for unresectable gastric cancer: Global?Asian?Japanese?
Takako Nakajima
2. Clinical Implication of Morphological Changes of Ramucirumab in Metastatic Gastric Cancer
Naoki Izawa, Hiroyuki Arai, Takuro Mizukami, Yoshiaki Horie, Mami Hirakawa, Takashi Ogura, Takashi Tsuda, Yu Sunakawa, Takako Nakajima
3. Early morphologic change (EMC) caused by regorafenib (REGO) in patients (pts) with metastatic colorectal cancer (mCRC)
Arai H, Miyakawa K, Denda T, Mizukami T, Horie Y, Izawa N, Hirakawa M, Ogura T, Tsuda T, Nakajima TE
4. JACCRO CC-11 安全性
Yu Sunakawa
5. CEA response and DpR (JACCRO CC-05/06)
Yu Sunakawa

学会発表(国際学会)

2017.04 American Association for Cancer Research

1. Identification of a FGFR3-TACC3 fusion in esophageal cancer
T. Mizukami, K. Sakai, S. Naruki, T. Taniyama, Y. Horie, N. Izawa, T. Tsuda, T. Fujino, N. Boku, H. Yasuda, T. Fukunaga, T. Eguchi Nakajima, K. Nishio

2017.06 Multinational Association of Supportive Care in Cancer

1. What are the barriers to and facilitators for the implementation of early palliative care in Japan?
Takako Eguchi Nakajima

2017.09 European Society for Medical Oncology

1. Dynamic changes in levels of gene mutations using circulating DNA and efficacy of 1st-line modified FOLFOXIRI plus bevacizumab for metastatic colorectal cancer harboring RAS mutation (JACCRO CC-11)
Y. Sunakawa, T. Sekikawa, J. Usher, H. Satake, Y. James, Y. Miyamoto, M. Nakamura, K. Kazama, A. Takagane, A. Makiyama, K. Kobayashi, Y. Kubota, M. Mori, M. Kotaka, M. Takeuchi, M. Fujii, K. Danenberg, H. Lenz, W. Ichikawa

1. Fluoropyrimidine (F) alone versus F plus platinum (P) as 1st-line chemotherapy in patients (pts) with advanced gastric cancer (AGC) and severe peritoneal metastasis (SPM): A multicenter observational study.
Hiroyuki Arai, Satoru Iwasa, Narikazu Boku, Masahiro Kawahira, Hirofumi Yasui, Toshiki Masuishi, Kei Muro, Shuichi Hironaka, Naoki Fukuda, Daisuke Takahari, Takako Eguchi Nakajima
2. Initial therapy with FOLFOXIRI plus bevacizumab (bev) for RAS mutant metastatic colorectal cancer (mCRC) and gene mutations in circulating tumor DNA (ctDNA) as a predictive marker for the efficacy: JACCRO CC-11.
Yu Sunakawa, Hironaga Satake, Joshua L. Usher, Yolanda S Jaimes, Yuji Miyamoto, Masato Nakamura, Hiroshi Nakayama, Nobuhiro Sugano, Akinori Takagane, Masahiro Gotoh, Takanori Watanabe, Kiyoshi Ishigure, Chihiro Tanaka, Masahiro Takeuchi, Masashi Fujii, KATHLEEN DANENBERG, Heinz-Josef Lenz.

論文業績(和文)

《原著・総説・解説》

1. 食道癌

- 薬局, 67: 1383-1386, 2016.3
- 谷山智子, 朴 成和

2. 胃癌

- 薬局, 67: 1389-1392, 2016.3.
- 堀江良樹, 朴 成和

3. 大腸癌

- 薬局, 67: 1393-1400, 2016.3.
- 伊澤直樹, 朴 成和

4. 胃がん 1) ファーストラインの選択 (S-1+CDDP 療法のエビデンスと実際)

- うまく続ける！消化管がん薬物療法の基本とコツ, 45-51, 2016.4.
- 中島貴子

5. 食道がん、胃がん、大腸がんに対する immune checkpoint 阻害薬の開発状況

- 腫瘍内科 17(1): 45-50, 2016.
- 津田享志、中島貴子

6. 化管神経内分泌腫瘍の薬物療法 新たな展開

- 腫瘍内科 2016; 17 (2): 213-219.
- 伊澤直樹, 中島貴子

7. がん:切除不能・再発. 日本メディカルセンター 消化器がん化学療法

- 臨床消化器内科6月増刊号 31(7): 182-188, 2016
- 堀江良樹、中島貴子

8. 密医療を目指した胃がんに対する殺細胞性抗悪性腫瘍薬・分子標的治療薬

- 腫瘍内科 17 (5): 493-499, 2016.
- 水上拓郎、津田享志、中島貴子

9. 切除不能・再発胃がんの新薬・バイオマーカー開発の現状と展望

- Mebio 33 (7): 12-18, 2016.
- 水上拓郎、小倉孝氏、中島貴子

文業績(英文)

《原著・総説》

1. HIInfusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective coparison.

 - Mol Clin Oncol. 4(4): 603-606, 2016.2.
 - Tsuda T, Kyomori C, Mizukami T, Taniyama T, Izawa N, Horie Y, Hirakawa M, Ogura T, Nakajima T, Tsugawa K, Boku N
2. Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies.

 - Mol Carcinog. 2016.2.
 - Mizukami T, Togashi Y, Naruki S, Banno E, Terashima M, de Velasco MA, Sakai K, Yoneshige A, Hayashi H, Fujita Y, Tomida S, Nakajima TE, Fujino T, Boku N, Ito A, Nakagawa K, Nishio K
3. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.

 - Lancet Oncol 17(1):99-108, 2016.
 - Shuichi Hironaka, Naotoshi Sugimoto, Kensei Yamaguchi, Toshikazu Moriwaki, Yoshito Komatsu, Tomohiro Nishina, Akihito Tsuji, Takako Eguchi Nakajima, Masahiro Gotoh, Nozomu Machida, Hideaki Bando, Taito Esaki, Yasunori Emi, Takashi Sekikawa, Shigemi Matsumoto, Masahiro Takeuchi, Narikazu Boku, Hideo Baba, Ichinosuke Hyodo
4. Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer.

 - Cancer Chemother Pharmacol DOI 10.1007/s00280-016-2972-3
 - Hideki Ueno, Masafumi Ikeda, Makoto Ueno, Nobumasa Mizuno, Tatsuya Ioka, Yasushi Omuro, Takako Eguchi Nakajima, Junji Furuse

5. Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205).

- Gastric cancer epub DOI 10.1007/S10120-016-0610-8
- Shitara K, Doi T, Nagano O, Imamura CK, Ozeki T, Ishii Y, Tsuchihashi K, Takahashi S, Nakajima TE, Hironaka S, Fukutani M, Hasegawa H, Saya H, Ohtsu A

6. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).

- Annals of Oncology epub DOI:10.1093/annonc/mdw206
- Yamazaki K, Nagase M, Tamagawa H, Ueda S, Tamura T, Murata K, Eguchi Nakajima T, Baba E, Tsuda M, Moriwaki T, Esaki T, Tsuji Y, Muro K, Taira K, Denda T, Funai S, Shinozaki K, Yamashita H, Sugimoto N, Okuno T, Nishina T, Umeki M, Kurimoto T, Takayama T, Tsuji A, Yoshida M, Hosokawa A, Shibata Y, Suyama K, Okabe M, Suzuki K, Seki N, Kawakami K, Sato M, Fujikawa K, Hirashima T, Shimura T, Taku K, Otsuji T, Tamura F, Shinozaki E, Nakashima K, Hara H, Tsushima T, Ando M, Morita S, Boku N, Hyodo I